Addressing and communicating heterogeneous treatment effects for patient subpopulations: Challenges and opportunities.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 5, p. 920, doi. 10.1002/pst.2164
- Publication type:
- Article
Works matching IS 15391604 AND DT 2021 AND VI 20 AND IP 5
Results: 8
1
2
Encouragement of subgroup assessment by the FDA.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 5, p. 923, doi. 10.1002/pst.2163
- Publication type:
- Article
3
Heterogeneity in treatment effects across diverse populations.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 5, p. 929, doi. 10.1002/pst.2161
- By:
- Publication type:
- Article
4
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populations.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 5, p. 965, doi. 10.1002/pst.2123
- By:
- Publication type:
- Article
5
Decomposition analysis as a framework for understanding heterogeneity of treatment effects in non‐randomized health care studies.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 5, p. 945, doi. 10.1002/pst.2111
- Publication type:
- Article
6
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: The hardest problem there is.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 5, p. 939, doi. 10.1002/pst.2110
- Publication type:
- Article
7
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysis.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 5, p. 952, doi. 10.1002/pst.2077
- By:
- Publication type:
- Article
8
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 5, p. 917, doi. 10.1002/pst.2037
- Publication type:
- Article